[30] On April 21, 2026 , CMS declined to implement it in Part D for 2027 and extended the temporary GLP-1 Bridge through Dec 31, 2027 instead
continue increasing competition by introducing oral GLP-1, dual incretin and novel metabolic drugs
GLP-1 is naturally produced in your intestines after eating, and it performs several important functions: [1] Slows gastric emptying, helping you feel fuller longer Signals the brain to reduce hunger and increase satiety Helps regulate blood sugar by stimulating insulin release Reduces glucagon secretion (which normally raises blood sugar) The weight loss and pharmaceutical industries have been revolutionized by prescription GLP-1 agonist medications, but these come with significant drawbacks - they're expensive, require injections, and worst of all, come with some brutal side effects, including muscle loss, GI distress, horribly long stomach emptying (gastroparesis), cancer risk, and even blindness
Additionally, evaluating how these therapies interact with current antidiabetic treatments and determining their suitability for combination therapies may further enhance their clinical value